Dupuytren Literature: Circulating Biomarkers | Dupuytren Research Group

Dupuytren Literature: Circulating Biomarkers

These materials are available for nonprofit educational use. This repository is allowed by copyright disclaimer under title 17, Appendix E, section 107 of the United States Copyright Act. Under this statute, allowance is made for “fair use” for purposes such as criticism, comment, news reporting, teaching, scholarship, and research. As defined, fair use specifically applies to this repository.

Medline Title Search (Dupuytren + (Biomarker OR Circulat*))

The development and evaluation of preventative and disease-modifying treatments for Dupuytren disease will benefit from the identification of quantitative biomarkers to assess disease severity in real time, rather than retrospectively from longitudinal clinical history. Most biomarker work has focused on palmar tissue biopsies, but a circulating biomarker would greatly increase biomarker accessibility and usefulness. These publications involve assays of circulating biomarkers or biomarkers which could potentially be evaluated as such.

Selected Publications

  • Bartal AH, Stahl S, Karev A, Lichtig C. Dupuytren’s contracture studied with monoclonal antibodies to connective tissue differentiation antigens. Clin Exp Immunol. 1987/05/01 ed. 1987 May;68(2):457–63. (PDF)
  • Bucala R, Spiegel L a, Chesney J, Hogan M, Cerami a. Circulating fibrocytes define a new leukocyte subpopulation that mediates tissue repair. Mol Med. 1994;1(1):71–81. (PDF)
  • Burch PR. Dupuytren’s contracture: an auto-immune disease? J Bone Joint Surg Br. 1966;48(2):312–9. (PDF)
  • Campbell CA, Burdick MM, Dacus A, Morgan R, Strieter R. (2010) Case-Controlled Peri-operative Bone-Marrow Mediated Fibrocyte Function in Patients with Dupuytren’s Contracture. In: AAHS Session A1: Policy, Dupuytren’s, Flexor Tendon. (PDF)
  • Gudmundsson KG, Arngrímsson R, Arinbjarnarson S, Olafsson A, Jonsson T. (1998) T-and B-lymphocyte subsets in patients with Dupuytren’s disease. Correlations with disease severity. J Hand Surg Br. 23(6):724-7. (PDF)
  • Heinemeier K, Langberg H, Kjaer M. Exercise-induced changes in circulating levels of transforming growth factor-beta-1 in humans: methodological considerations . Eur J Appl Physiol. 2003; 90 ( 1-2 ):17–171. (PDF)
  • Houghton S, Holdstock G, Cockerell R, Wright R. (1983) Dupuytren’s contracture, chronic liver disease and IgA immune complexes. Liver. Aug;3(4):220-4. (PDF)
  • Iqbal SA, Hayton MJ, Watson JS, Szczypa P, Bayat A. First identification of resident and circulating fibrocytes in Dupuytren’s disease shown to be inhibited by serum amyloid P and Xiapex. PLoS One. 2014;9(6):e99967. (PDF)
  • Józsa L, Salamon A, Réffy A, Renner A, Demel S, Donhöffer A, et al. Fine structural alterations of the palmar aponeurosis in Dupuytren’s contracture. A combined scanning and transmission electron microscopic examination. Zentralbl Allg Pathol. 1988/01/01 ed. 1988 Jan;134(1):15–25. (PDF)
  • Kanaris C, John S, Hankinson J, Bayat A, Stanley JK, Ollier WER. Presentation Abstract: MMP14 Gene Polymorphism is Strongly Associated with Dupuytren’s Disease. Hand. 2006;1(1):19–61. (PDF)
  • Mayerl C, Del Frari B, Parson W, Boeck G, Piza-Katzer H, Wick G, et al. Characterisation of the inflammatory response in Dupuytren’s disease. J Plast Surg Hand Surg. 2016;6764(February):1–9. (PDF)
  • McCarty S, Syed F, Bayat A. Role of the HLA System in the Pathogenesis of Dupuytren’s Disease. Hand (N Y). 2011/09/03 ed. 2010 Sep;5(3):241–50. (PDF)
  • Menni C, Kiddle SJ, Mangino M, Vinuela a., Psatha M, Steves C, et al. Circulating Proteomic Signatures of Chronological Age. Journals Gerontol Ser A Biol Sci Med Sci. 2014;(3):1–9. (PDF)
  • Menzel EJ, Piza H, Zielinski C, Endler AT, Steffen C, Millesi H. Collagen types and anticollagen-antibodies in Dupuytren’s disease. Hand. 1979;11(3):243–8. (PDF)
  • Menzel EJ, Neumuller J, Rietsch A, Millesi H. (1994) Connective Tissue Autoantibodies in Dupuytren’s Disease: Associations with HLA DR3. In: Dupuytren’s Disease Pathobiochemistry and Clinical Management, Springer-Verlag, 49–61. (PDF)
  • Noeva K, Karagantcheva S, Toshkov AS. Antigamma-globulin factors and levels of IgG, IgA and IgM in sera of patients with Dupuytren’s contracture. Acta Chir Plast. 1977;19(1):56-62. (PDF)
  • O’Gorman D, Howard JC, Varallo VM, Cadieux P, Bowley E, McLean K, Pak BJ, Gan BS. (2006) Identification of protein biomarkers in Dupuytren’s contracture using surface enhanced laser desorption ionization time-of-flight mass spectrometry (SELDI-TOF-MS). Clin Invest Med. 29(3):136-45. (PDF)
  • Pereira RS, Black CM, Turner SM, Spencer JD. Antibodies to collagen types I-VI in Dupuytren’s contracture. J Hand Surg Br. 1986/02/01 ed. 1986 Feb;11(1):58–60. (PDF)
  • Ratajczak-Wielgomas K, Gosk J, Rabczynski J, Augoff K, Podhorska-Okolów M, Gamian A, Rutowski R. (2012). Expression of MMP-2, TIMP-2, TGF-ß1, and Decorin in Dupuytren’s Contracture. Connective Tissue Research 53 (6): 469–77. (PDF)
  • Sachse C, Brenner P. Reactivity of Cells in Nodules of Dupuytren’s Contracture with Monoclonal Antibodies Recognizing Leukocyte Antigens and von Willebrand’s Factor. In: Dupuytren’s Disease Pathobiochemistry and Clinical Management. 1994;117–26. (PDF)
  • Shih B, Tassabehji M, Watson JS, Bayat A. DNA copy number variations at chromosome 7p14.1 and chromosome 14q11.2 are associated with Dupuytren’s disease: potential role for MMP and Wnt signaling pathway . Plast Reconstr Surg . 2011/12/21 ed. 2012; 129 ( 4 ):32–921. (PDF)
  • Shih B, Watson S, Bayat A. Whole genome and global expression profiling of Dupuytren’s disease: systematic review of current findings and future perspectives. 2012/07/10 ed. Annals of the Rheumatic Diseases. 2012. p. 1440–7. (PDF)
  • Tarlton JP, Meagher R, Brown D, Mcgrouther A, Afoke A. (1998). Mechanical Stress in Vitro Induces Increased Expression of MMPs 2 and 9 in Excised Dupuytren’s Disease Tissue. The Journal of Hand Surgery: Journal of the British Society for Surgery of the Hand 23 (3): 297–302. doi:10.1016/S0266-7681(98)80044-2. (PDF)
  • Ulrich D, Hrynyschyn K, Pallua N. Matrix metalloproteinases and tissue inhibitors of metalloproteinases in sera and tissue of patients with Dupuytren’s disease. (2003) Plast Reconstr Surg. 112(5):1279–1286. (PDF)
  • Wilkinson JM, Davidson RK, Swingler TE, Jones ER, Corps AN, Johnston P, Riley GP, Chojnowskid AJ, Clark IM. (2012) MMP-14 and MMP-2 are key metalloproteases in Dupuytren’s disease fibroblast-mediated contraction Biochimica et Biophysica Acta (BBA) – Molecular Basis of Disease 1822(6), 897–905. (PDF)
  • Zamora RL, Heiglits R, Kraemer BA, Louis S, Erlich HP, Goner P, et al. Presence of growth factors in palmar and plantar fibromatoses. J Hand Surg Am. 1994;19(3):435–41. (PDF)

Dupuytren Literature